Therefore, our findings suggest that efforts to inhibit ERG function in prostate cancer should focus on the role of ERG in transcriptional activation, which is required for tumor-promoting activities both in the presence and absence of AKT activation. The gene discussed is AKT1; the disease is Familial prostate cancer.